Ascione Raimondo

GMC: 4392194

Hospital(s): University Hospital Bristol NHS FT

Special Interests: Adult Cardiac Surgery

Professor Ascione is an active NHS Consultant in Adult Cardiac Surgery at the Bristol Heart Institute, University Hospital Bristol NHS Foundation Trust, since 2002. During this time he has carried out >3700 heart operations as Chief Surgeon with an overall survival of 99.1%.

He is an international expert in the areas of:

·       Mitral Valve Repair (>900 operations; repair success rate >90%; survival >99%)

·       Beating Heart Coronary Bypass Surgery (>1350 procedures, survival >99%)

·       Aortic Valve surgery (>400 procedures; survival >99%)

·       Ablation of Atrial Fibrillation

·       Ischemic Heart Failure

·       Combined surgical procedures

 He moved from near Pompei in Italy to UK in 1997 to stay. He was appointed by the University of Bristol and the local NHS Trust as Consultant Senior Lecturer in Cardiac Surgery in 2002, promoted to Reader in 2006, and to Professor of Adult Cardiac Surgery in 2010.

He holds or has held senior leadership/management roles in his University and NHS Institutions and internationally. Examples include: Clinical Director of Bristol Heart Institute (BHI) Hospital (2013-15); BHI Governance Lead (2019 to date); Founder and Director of the Translational Biomedical Research Centre (TBRC) – University of Bristol since 2015; Chair of the University BHI  Research Steering Committee (2010-13 elected);  Member of the Nucleus of the Cardiovascular Working Group of the European Society of Cardiology (2010-16); Member of the Academy of the European Association of Cardio-Thoracic Surgery 2009-12; Member of the Foundation for Polish Science – International Interdisciplinary Panel of Experts since 2017; Member of the Novel and Emerging Technologies (NET) Grants Committee (Heart Research UK) since 2017; Member of the Italian International Experts Research Project Panel – MIUR since 2014.

Professor Ascione is the recipient of NHS National Clinical Excellence Silver Award since 2013 for his outstanding performance, the Garfield Weston Trust Senior Lectureship in Cardiac Surgery (2003-08), the Fellowship ad eundeum by the Royal College of Surgeons of England in 2004, the Master of Surgery by University of Bristol in 2002, the John Parker Gold Medal by the UK Society of Cardiothoracic Surgeons in 2001, and he was part of the Bristol Team awarded the “UK Surgical Team of Year – 2005” by UK Hospital Doctors.

Since 2014, he has developed an extensive multidisciplinary research network of national/international biomedical scientists, clinicians and industry as a national biomedical leader testing at clinical standards at TBRC new drugs and biomedical devices as a final step validation prior to first-in-human trials. Within this new biomedical context, he is developing 3 new drugs to treat heart attack, new biodegradable vascular stents to treat vascular blockages through a needle, new polymeric heart valves for surgical or percutaneous treatment, new tissue engineered vascular grafts for adult applications, new stem cell and gene-based therapies for cardiovascular applications. 

The total value of his research grants and capital bids is currently in excess of £53M awarded by top UK/EU funding bodies including NIHR, BHF, MRC, INNOVATE UK, EC Horizon 2020 and more. 

His current research interests include:

·       First in man Clinical Trials in adult Cardiac Surgery to reduce post-operative complications

·       |Smart surgical Instrumentation and Robotic devices

·       Testing a new heart polymeric valve and a new biodegradable vascular stent

·       Small Arteries Tissue Engineering, Stem Cells and Cardiac Regeneration

·       Coronary micro-vascular dysfunction

·       Diabetes, Obesity, Stroke, Infections, Wound Healing, Mitral Valve Repair.

 

He enjoys spending his free time with his family and friends, philanthropy, classic music, opera, cycling, sea, and sand.

View external profile →

Training Attended
Qualifications & Accreditations
  • FRCS ad eundeum – Royal College of Surgeon of England, 2004
  • FETCS – European Board of Thoracic and Cardiovascular Surgeons, Vienna, Austria; 2003.
  • ChM – Master of Surgery, University of Bristol, UK, 2002
  • Specialist in Cardiac Surgery (FRCS-CTh equiv) University-Hospital Federico II, Naples, Italy; 1994
  • State Exam (FRCS equiv) University-Hospital Federico II, Naples, Italy; 1994.
  • MB BCh (Bachelor of Medicine and Surgery), University of Naples, Italy; 1993
  • Classic High School Diploma, Torre del Greco, Naples, Italy 1985
Additional Information

Risk-adjusted in-hospital survival rate

This graph shows the “in hospital” survival rate of patients who are operated on by the individual surgeon/unit you have selected. “In hospital” means time the patient is in the hospital where they have had their operation. It does not include any time that patients may have spent in other hospitals, either before or after their heart operation.

The data has been through a complex methodology, including the variations in patient risk factors in order to give you a comparative base from which to work from. This means that the survival rates take into account the type and risk of patients being operated on for each surgeon/unit. This is known as risk adjusted survival.

The vertical axis shows the GMC number of the surgeon or the Hospital identifier. In brackets is the total number of patients operated on by the surgeon/unit and the percentage of patients for whom the survival is known. The horizontal axis is the percentage survival. The dashed vertical line shows the risk adjusted survival rate for the UK as a whole. The solid black horizontal line represents the surgeon/unit. What is important here is that the horizontal line crosses the vertical dashed line. If this occurs, it means that the surgeon/unit are within the expected outcomes given the case-mix and risk factors of the patients they operate on.

The icons that sit on the horizontal line should give you more information about your surgeon/team.

For example

The open square is the survival rate with no risk adjustments:
The X is the predicted survival with adjustments
The solid dot is the survival probability after the methodology has been applied.

  • If the solid dot is red it means survival is worse than expected
  • If the solid dot is black it means that it is within limits
  • If the solid dot is green it means that there is significantly higher survival than expected

There is a lot of information on these plots, but the takeaway message is that if the solid black line crosses the dashed vertical line then the survival rate for the surgeon/unit is within expectations and that there is no reason for any concern.

A more detailed explanation about these graphs and methodology can be found here: Graph Explanations